

DEC 16 2004



GlaxoSmithKline

## FAX

To 1624  
.....  
Company USPTO  
.....  
Fax 703-872-9306  
.....  
From Julie D. McFalls  
.....  
Tel 919-483-1545 Fax 919-483-7988  
.....  
E-mail Julie.D.McFalls@gsk.com  
.....  
Date December 16, 2004 Pages including cover 15  
.....  
Subject Serial No.: 09/980,987  
.....  
Filing Date: November 6, 2001  
.....

Glaxo Wellcome Inc.  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
www.gsk.com


### Attached:

Certificate of Transmission  
Fee Transmittal for FY 2005  
Amendment  
Terminal Disclaimer to Obviate A Double Patenting Rejection Over a Prior Patent

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

DEC 16 2304

P.2/15

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)		Docket No. PU3611USw
Applicant(s): David COLCLOUGH et al.		
Application No. 09/980,987	Filing Date November 6, 2001	Examiner B. Coleman
		Group Art Unit 1624
Invention: 1,5-BENZODIAZEPINE DERIVATIVES		
I hereby certify that this _____ Fee Transmittal, Amendment, Terminal Disclaimer <small>(Identify type of correspondence)</small>		
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)		
on December 16, 2004 <small>(Date)</small>		
Julie D. McFalls <small>(Typed or Printed Name of Person Signing Certificate)</small>		
 <small>(Signature)</small>		
Note: Each paper must have its own certificate of mailing.		

PTO/SB/17 (10-03)  
Approved for use through 07/31/2008, OMB 0851-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) \$110.00

## Complete if Known

Application Number 09/980,987  
Filing Date November 6, 2001  
First Named Inventor David COLCLOUGH et al.  
Examiner Name B. Coleman  
Art Unit 1624  
Attorney Docket No. PU3611USw

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 07-1392

Deposit Account Name GlaxoSmithKline

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1001	790	2001 395 Utility filing fee	
		1002	350	2002 175 Design filing fee	
		1003	550	2003 275 Plant filing fee	
		1004	790	2004 395 Reissue filing fee	
		1005	160	2005 80 Provisional filing fee	
SUBTOTAL (1)					(\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND

Total Claims	Extra Claims	Fee from below	Fee Paid
	-20** =	0 X	0.00
Independent Claims	-3** =	0 X	0.00
Multiple Dependent			

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1202	18	2202 9 Claims in excess of 20	
		1201	88	2201 44 Independent claims in excess of 3	
		1203	300	2203 150 Multiple dependent claim, if not paid	
		1204	68	2204 44 ** Reissue independent claims over original patent	
		1205	18	2205 9 ** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$) \$0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1051	130	2051 65 Surcharge - late filing fee or oath	
		1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet	
		1053	130	1053 130 Non - English specification	
		1812	2,520	1812 2,520 For filing a request for ex parte reexamination	
		1804	920*	1804 920* Requesting publication of SIR prior to Examiner action	
		1805	1,840*	1805 1,840* Requesting publication of SIR after Examiner action	
		1251	110	2251 55 Extension for reply within first month	
		1252	430	2252 215 Extension for reply within second month	
		1253	980	2253 490 Extension for reply within third month	
		1254	1,530	2254 785 Extension for reply within fourth month	
		1255	2,080	2255 1,040 Extension for reply within fifth month	
		1401	340	2401 170 Notice of Appeal	
		1402	340	2402 170 Filing a brief in support of an appeal	
		1403	300	2403 150 Request for oral hearing	
		1451	1,510	1451 1,510 Petition to institute a public use proceeding	
		1452	110	2452 55 Petition to revive - unavoidable	
		1453	1,370	2453 685 Petition to revive - unintentional	
		1501	1,370	2501 685 Utility issue fee (or reissue)	
		1502	490	2502 245 Design issue fee	
		1503	660	2503 330 Plant issue fee	
		1460	130	1460 130 Petitions to the Commissioner	
		1807	50	1807 50 Processing fee under 37 CFR § 1.17(q)	
		1806	180	1806 180 Submission of Information Disclosure Statement	
		8021	40	8021 40 Recording each patent assignment per property (times number of properties)	
		1809	790	2809 365 Filing a submission after final rejection (37 CFR § 1.129(a))	
		1810	780	2810 395 For each additional invention to be examined (37 CFR § 1.129(b))	
		1801	780	2801 385 Request for Continued Examination (RCE)	
		1802	900	1802 900 Request for expedited examination of a design application	
Other fee (specify) Terminal Disclaimer					110.00

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) \$110.00

## SUBMITTED BY

Name (Print/Type) Bonnie L. Deppenbrock

Registration No. 28,209  
(Attorney/Agent)

## Complete (if applicable)

Telephone 919 483-1577

Signature

Bonnie L. Deppenbrock

Date December 16, 2004

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS OFFICE. USPTO, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL  
for FY 2005**

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** \$110.00**Complete if Known**

Application Number	09/980,987
Filing Date	November 6, 2001
First Named Inventor	David COLCLOUGH et al.
Examiner Name	B. Coleman
Art Unit	1624
Attorney Docket No.	PU3611USw

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number	07-1392
Deposit Account Name	GlaxoSmithKline

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 790	2001 395	Utility filing fee	
1002 350	2002 175	Design filing fee	
1003 550	2003 275	Plant filing fee	
1004 790	2004 395	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)			

**2. EXTRA CLAIM FEES FOR UTILITY AND**

Total Claims	Extra Claims	Fee from below	Fee Paid
	-20** =	0 X	0.00
Independent Claims	-3** =	0 X	0.00
Multiple Dependent			

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 88	2201 44	Independent claims in excess of 3	
1203 300	2203 150	Multiple dependent claim, if not paid	
1204 88	2204 44	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)			\$0.00

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non - English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 430	2252 215	Extension for reply within second month	
1253 960	2253 480	Extension for reply within third month	
1254 1,530	2254 765	Extension for reply within fourth month	
1255 2,080	2255 1,040	Extension for reply within fifth month	
1401 340	2401 170	Notice of Appeal	
1402 340	2402 170	Filing a brief in support of an appeal	
1403 300	2403 150	Request for oral hearing	
1451 1,510	1451 1,510	Petition to Institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,370	2453 685	Petition to revive - unintentional	
1501 1,370	2501 685	Utility issue fee (or reissue)	
1502 490	2502 245	Design issue fee	
1503 660	2503 330	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR § 1.17(q)	
1808 180	1808 180	Submission of Information Disclosure Statement	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 790	2809 395	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810 790	2810 395	For each additional invention to be examined (37 CFR § 1.129(b))	
1801 790	2801 395	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify) <u>Terminal Disclaimer</u>			110.00

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)** \$110.00**SUBMITTED BY**

Name (Print/Type) Bonale L. Deppenbrock

**Registration No.**

(Attorney/Agent)

28,209

**Complete (if applicable)****Telephone**

919 483-1577

**Signature***Bonale L. Deppenbrock***Date**

December 16, 2004

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS OFFICE.

PU3611USw

CENTRAL MAIL ROOM

DEC 16 2004

1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: David Colclough et al.  
Application Serial No.: 09/980,987 Art Unit: 1624  
Filing Date: November 6, 2001 Examiner: B. Coleman  
Title: 1,5-BENZODIAZEPINE  
DERIVATIVES

---

**Commissioner for Patents  
Washington, D.C. 20231**

**AMENDMENT**

Sir:

This amendment is responsive to the Office Action mailed September 28, 2004. Please amend the application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2.

Remarks/Arguments begin on page 7.